Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - MusclePharm CorpFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR4.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR8.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR1.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR7.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR9.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR6.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR2.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR3.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR34.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR36.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR25.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR47.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR50.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR45.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR17.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR30.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR44.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR39.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR40.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR31.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR55.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR28.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR52.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR37.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR33.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR46.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR16.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR12.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR53.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR13.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR43.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR32.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR11.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR18.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR14.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR24.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR29.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR48.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR42.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR22.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR15.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR23.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR35.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR5.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR21.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR38.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR10.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR20.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR26.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR51.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR49.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR41.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR27.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR19.htm
XML - IDEA: XBRL DOCUMENT - MusclePharm CorpR54.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

(Amendment No. 1)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: September 30, 2012

 

OR

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________to ______________

 

Commission File Number: 000-53166

 

MUSCLEPHARM CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada   77-0664193

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

4721 Ironton Street, Building A

Denver, Colorado 80239

(Address of principal executive offices and zip code)

 

(303) 396-6100

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files. Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

  

Large accelerated filer o   Accelerated filer o
Non-accelerated filer o   Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

 

As of November 8, 2012, there were 2,287,373,504 shares outstanding of the registrant’s common stock.

 

 
 

 

Explanatory Note

 

The sole purpose of this Amendment No. 1 (this “Amendment”) to MusclePharm Corporation’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on November 13, 2012 (the “Form 10-Q”), is to furnish Exhibit 101, which provides the XBRL (eXtensible Business Reporting Language) Interactive Data Files for the financial statements and notes included in Part I, Item 1 of the Form 10-Q.

 

No other modifications or changes have been made to the Form 10-Q. This Amendment speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date and does not modify or update in any way disclosures made in the original Form 10-Q.

 

Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

 

 
 

 

 

Item 6. Exhibits.

 

Exhibit No.  Description
   
31.1*  Rule 13 (A) – 14(A) Certification of Principal Executive Officer
   
31.2*  Rule 13 (A) – 14(A) Certification of Principal Financial Officer
   
32.1*  Section 1350 Certification of Principal Executive Officer
   
32.2*  Section 1350 Certification of Principal Financial Officer
   
101.INS** XBRL Instance Document
   
101.SCH** XBRL Taxonomy Extension Schema
   
101.CAL** XBRL Taxonomy Extension Calculation Linkbase
   
101.DEF** XBRL Taxonomy Extension Definition Linkbase
   
101.LAB** XBRL Taxonomy Extension Label Linkbase
   
101.PRE** XBRL Taxonomy Extension Presentation Linkbase

 

* These exhibits were previously included in MusclePharm Corporation’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012, filed with the Securities and Exchange Commission on November 13, 2012.

 

** In accordance with Regulation S-T, the XBRL-related information on Exhibit No. 101 to this Quarterly Report on Form 10-Q shall be deemed “furnished” herewith and not “filed.”

 

 

 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MUSCLEPHARM CORPORATION
       
       
Date: November 16, 2012 By: /s/ Brad J. Pyatt  
    Name: Brad J. Pyatt  
    Title: Chief Executive Officer and President 
(Principal Executive Officer)
 
       
       
Date: November 16, 2012 By: /s/ L. Gary Davis  
    Name: L. Gary Davis  
   

Title: Chief Financial Officer

(Principal Financial Officer)

(Principal Accounting Officer)